阿卡波糖治疗糖耐量减低人群效果的Meta分析  

Meta-analysis on the Efficacy of Acarbose Therapy on Chinese Patients with Impaired Glucose Tolerance

作　　者：刘雷[1] 张连生[1] 梅勇[1] 章月潇[1] 刘丽[1] 

机构地区：[1]武汉科技大学医学院公共卫生学院,湖北省武汉市430065

出　　处：《中国全科医学》2013年第14期1637-1640,共4页Chinese General Practice

摘　　要：目的评价阿卡波糖对我国糖耐量减低(IGT)人群的治疗效果。方法检索万方数据库、维普资讯、PubMed、The Cochrane Library、西文生物医学期刊文献数据库,收集2000—2012年公开发表使用阿卡波糖治疗IGT的临床随机对照试验。采用RevMan 5.1软件对符合条件的文献进行Meta分析,各研究之间进行异质性检验,使用固定效应模型计算合并RR值和95%可信区间(CI),并用漏斗图查看发表偏倚。结果共检索出503篇有关阿卡波糖治疗IGT的文献,其中21篇文献符合纳入标准,包含2 461例试验对象,其中治疗组1 243例,对照组1 218例。Meta分析结果显示,合并RR=0.37,95%CI(0.29,0.48),阿卡波糖组治疗IGT转归为糖尿病的发生率是对照组的37%,差异有统计学意义(P<0.05)。漏斗图显示图形基本对称。结论阿卡波糖对IGT人群的治疗效果良好,能减少或延缓2型糖尿病的发生。Objective To evaluate the efficacy of acarbose therapy on Chinese patients with impaired glucose tolerance （IGT）. Methods Databases including Wanfang Data, VIP, PubMed, The Cochrane Library, Foreign Medical Journal Serv- ice （FMSJ） were systematically searched to collect randomized controlled clinical trials of acarbose treatment on subjects with IGT from the year 2000 to 2012 and relevant references were also manually retrieved in selected articles. The studies were screened according to predefined inclusion and exclusion criteria. The extracted data were analyzed with RevMan 5.1 software and Chi - square for heterogeneity test. Fixed effect model was used to calculate combined RR value and 95% confidence interval. Funnel plot was used to show statistical bias. Results A total of 503 publications of studies on acarbose treating IGT were retrieved. This study included 21 trials involving 2 461 subjects, 1 243 in the treatment group and 1 218 controls. Incidence of diabetic outcome in the treatment group was 37% that in the control group [RR =0. 37, 95% CI （0. 29, 0.48）, P 〈0. 055. Funnel plot revealed no significant publication bias. Conclusion Acarbosc could be used to reduce or delay the development of type 2 diabetes in patients with IGT.

关 键 词：阿卡波糖 糖耐量减低 糖尿病 2型 META分析 

分 类 号：R587.1[医药卫生—内分泌]